BIRTH CONTROL PILLS MAY INCREASE BREAST CANCER RISK
Women who recently
used birth control pills containing high-dose estrogen and a few other
formulations had an increased risk for breast cancer, whereas women using some
other formulations did not, according to data published in Cancer
Research, a journal of the
American Association for Cancer Research.
Our
results suggest that use of contemporary oral contraceptives [birth control
pills] in the past year is associated with an increased breast cancer risk
relative to never or former oral contraceptive use, and that this risk may vary
by oral contraceptive formulation," said Elisabeth F. Beaber, PhD, MPH, a
staff scientist in the Public Health Sciences Division of Fred Hutchinson
Cancer Research Center in Seattle, Washington.
"Our
results require confirmation and should be interpreted cautiously," added
Beaber. "Breast cancer is rare among young women and there are numerous
established health benefits associated with oral contraceptive use that must be
considered. In addition, prior studies suggest that the increased risk
associated with recent oral contraceptive use declines after stopping oral
contraceptives."
In
a nested case-control study of 1,102 women diagnosed with breast cancer and
21,952 controls, Beaber and colleagues found that recent oral contraceptive use
increased breast cancer risk by 50 percent, compared with never or former use.
All study participants were at Group Health Cooperative in the Seattle-Puget
Sound area. Patients received a cancer diagnosis between 1990 and 2009.
Birth
control pills containing high-dose estrogen increased breast cancer risk
2.7-fold, and those containing moderate-dose estrogen increased the risk
1.6-fold. Pills containing ethynodiol diacetate increased the risk 2.6-fold,
and triphasic combination pills containing an average of 0.75 milligrams of
norethindrone increased the risk 3.1-fold.
Birth
control pills containing low-dose estrogen did not increase breast cancer risk.
About
24 percent, 78 percent, and less than 1 percent of study controls who were
recent oral contraceptive users filled at least one prescription in the past
year for low-, moderate-, and/or high-estrogen dose oral contraceptives,
respectively, according to Beaber.
Unlike
most previous studies that depended on women's self-report or recall, which may
cause bias,
Beaber
and colleagues used electronic pharmacy records to gather detailed information
on oral contraceptive use including drug name, dosage, and duration of
medication.
Comments
Post a Comment